22 February 2024
22 February 2024
Codeine linctus has been reclassified from a pharmacy-only medicine to a prescription-only medicine in the UK.
Novartis is recalling the product as the MHRA no longer deems its benefit-risk balance favourable.
Bavarian Nordic reported a preliminary revenue of $1bn for 2023, driven by sales of JYNNEOS, its mpox/smallpox vaccine.
US patients are travelling to avoid abortion bans, but a new study has found telehealth prescriptions to be safe and effective.
Polpharma Biologics’ biosimilar candidate PB106 showed non-inferiority to the reference therapy, Takeda’s Entyvo.
A Phase I trial studying the therapy is underway after an FDA clinical hold was lifted last year, with initial data expected in 2024.
Its decision on the regulatory approval for linvoseltamab is anticipated by 22 August 2024.
Charles River’s clients will gain access to Wheeler’s portable Chemistry, Manufacturing and Controls (CMC) platform.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
